TITLE

Efficacy and Safety of Rivastigmine in the Treatment of Behavioural and Psychological Symptoms in Chinese Dementia Patients: an Open-Label Study

AUTHOR(S)
Chan, C. F.; Chan, W. C.; Li, S. W.
PUB. DATE
September 2006
SOURCE
Hong Kong Journal of Psychiatry;2006, Vol. 16 Issue 3, p101
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives: Behavioural and psychological symptoms of dementia are integral features of Alzheimer's disease. They have been recognised as important predictors for premature institutionalisation and constitute major caregiver burdens. This study examined the efficacy of rivastigmine in the treatment of behavioural and psychological symptoms of dementia in Chinese older adults suffering from mild-to-moderately severe Alzheimer's disease, under conditions reflecting everyday clinical care. Rivastigmine tolerability and its effects on cognition and functional status were also assessed. Patients and Methods: This was a 20-week prospective, open-label, single-centre study. Twenty four psychogeriatric outpatients, who fulfilled DSM-IV diagnosis criteria for Dementia of the Alzheimer's Type and exhibited behavioural and psychological symptoms of dementia, were treated with flexible doses of rivastigmine. Clinical responses were evaluated using the Chinese version of the Neuropsychiatric Inventory (CNPI), the Cantonese version of the Mini-Mental State Examination (CMMSE), and Functional Assessment Staging (FAST). Results: At week 20, the mean CNPI total score decreased by 19.5 (p < 0.001) with significant improvements regarding delusions, depression / dysphoria, apathy, disinhibition, irritability / lability, aberrant motor behaviour, and night-time behaviour disturbance. Clinically significant reductions in behavioural and psychological symptoms of dementia were observed in 20 (83%) of the patients. The percentage change in CNPI total score correlated with percentage change in CNPI caregiver distress score (Spearman's rho = 0.8, p < 0.001), but not with the rivastigmine dosage (Spearman's rho = 0.004, p = 0.99) or change in CMMSE score (Spearman's rho = -0.175, p = 0.41). No significant changes in CMMSE and FAST scores were demonstrated. The mean + SD daily dose of rivastigmine was 9 + 3 mg. Rivastigmine was well-tolerated in general, though a significant mean weight loss of 2 kg (p < 0.001) was noted. Conclusion: This study suggested that rivastigmine was well-tolerated and effective in improving behavioural and psychological symptoms of dementia in Chinese patients with mild-to-moderately severe Alzheimer's disease. Its beneficial effect on behavioural and psychological symptoms of dementia was independent of dosage and cognitive response. More rigorous investigations are needed to confirm and clarify the potential therapeutic role of the drug in ameliorating behavioural and psychological symptoms of dementia.
ACCESSION #
28159015

 

Related Articles

  • Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. Connelly, P. J.; Prentice, N. P.; Fowler, K. G. // Journal of Neurology, Neurosurgery & Psychiatry;Mar2005, Vol. 76 Issue 3, p320 

    Objective: To investigate the possibility that response to cholinesterase inhibitor therapy could be predicted by easily measurable variables that are known to change as a result of treatment (such as the Mini Mental State Examination), measures of function (such as the instrumental activities...

  • EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. Kogan, E. A.; Korczyn, A. D.; Virchovsky, R. G.; Klimovizky, S. Sh.; Treves, T. A.; Neufeld, M. Y. // Journal of Neural Transmission;Oct2001, Vol. 108 Issue 10, p1167 

    Summary. In this pilot study, we examined the long-term treatment effect of donepezil on the quantitative EEG (qEEG) in 12 Alzheimer's disease patients. The qEEGs of the mean absolute and relative amplitudes of betal, alpha, theta and delta activities were obtained at baseline and during...

  • Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. Rainer, M.; Mucke, H. A. M.; Krüger-Rainer, C.; Kraxberger, E.; Haushofer, M.; Jellinger, K. A. // Journal of Neural Transmission;Nov2001, Vol. 108 Issue 11, p1327 

    Summary. In a cross-sectional study of outpatients diagnosed with dementia of the Alzheimer type who had been treated with a broad variety of drugs supposed to improve cognition or to delay cognitive decline, we have investigated the effects of abruptly discontinuing therapy on cognition....

  • Concurrent use of cholinesterase inhibitors, anticholinergics common.  // PharmacoEconomics & Outcomes News;1/15/2005, Issue 469, p9 

    Discusses the use of acetylcholine receptor antagonists by patients who receive cholinesterase inhibitors for Alzheimer's disease. Percentage of those who received inhibitors that also use the antagonists; Significance of the antagonists to the treatment of Alzheimer's disease; Importance of...

  • Guidelines for the Appropriate Use of Cholinesterase Inhibitors in Patients with Alzheimer's Disease. Schachter, A.S.; Davis, K.L. // CNS Drugs;1999, Vol. 11 Issue 4, p281 

    The cholinesterase inhibitors are the only available scientifically proven symptomatic treatments for dementia of the Alzheimer's type. The guidelines we present summarise the current updated knowledge on the available drugs, including tacrine, donepezil, rivastigmine, metrifonate and...

  • Defining Treatment Response to Donepezil in AlzheimerÂ’s Disease: Responder Analysis of Patient-Level Data from Randomized, Placebo-Controlled Studies. Burns, Alistair; Yeates, Andrew; Akintade, Latif; del Valle, Megan; Zhang, Richard Y.; Schwam, Elias M.; Perdomo, Carlos A. // Drugs & Aging;2008, Vol. 25 Issue 8, p707 

    BACKGROUND: Defining treatment success in progressive diseases, such as Alzheimer’s disease (AD), can be challenging. OBJECTIVE: To explore the impact of employing different criteria to define a treatment ‘responder’ using analyses of patient-level data from randomized,...

  • galantamine.  // Royal Society of Medicine: Medicines;2002, p261 

    The article presents information on galantamine. The drug is an anticholinesterase recently introduced for the symptomatic treatment of mild to moderate dementia of Alzheimer's disease. It is thought only to slow the rate of cognitive deterioration in about half of patients treated. Authorities...

  • Cholinesterase Inhibitors in Alzheimer's Disease: Are they Worth the Cost? Whitehouse, P.J. // CNS Drugs;1999, Vol. 11 Issue 3, p167 

    Several cholinesterase inhibitors have demonstrated their ability to improve cognition in Alzheimer's disease. This paper reviews issues important to determining whether cholinesterase inhibitors are worth their cost. Establishing therapeutic goals in Alzheimer's disease and assessing initial...

  • NICE turnaround on Alzheimer's. Baines, Emma // GP: General Practitioner;3/18/2005, p6 

    The article informs that National Institute for Clinical Excellence (NICE), UK government organisation, is expected to reverse its recommendation that cholinesterase inhibitors should not be given to Alzheimer's patients on the National Health Service (NHS), following criticism from a government...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics